From Witty To Walmsley – The Priorities For GSK's New CEO
It's Emma Walmsley's first week at the helm of GlaxoSmithKline. What can we expect in terms of her priorities?
You may also be interested in...
GlaxoSmithKline said its increasingly streamlined operations are on a growth trajectory, but that capacity constraints mean demand for its popular shingles vaccine will keep outstripping supply.
GSK has more than doubled its oncology pipeline since July 2018, and the company's CEO thinks smaller deals and a new site combining R&D and manufacturing will enable its progress to continue.
J.P. Morgan Notebook Day 2: Walmsley On Diversity, Amgen's Overseas Cash, Growing Opdivo, Mylan On US Generic Pricing, Boston's Pipeline And J&J In Alzheimer's
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: GSK's Walmsley looks to be a leader on diversity, Amgen talks tax reform and deals, Mylan raises the issue of generic drug shortages, Boston builds out its pipeline, and J&J is dealing in Alzheimer's disease.